Clinical Characteristics and Predictors of Mortality in Minority Patients Hospitalized with COVID-19 Infection

Rizwan Muhammad1 · Richard Ogunti1 · Basharat Ahmad1 · Muhammad Munawar1 · Sahai Donaldson1,2 · Mahbubur Sumon1,2 · Angesom Kibreab1,3 · Alicia N. Thomas1,2 · Alem Mehari1,2

Received: 11 November 2020 / Revised: 29 December 2020 / Accepted: 29 December 2020
© W. Montague Cobb-NMA Health Institute 2021, corrected publication 2022

Abstract
Objectives To identify the early mortality predictors in minority patients hospitalized with coronavirus disease 2019 (COVID-19).

Design Demographics, presenting characteristics, admission laboratory data, ICU admission, and mortality data were collected from 200 consecutively hospitalized patients with COVID-19.

Results The mean (SD) age was 58.9 (15.1) years, 121 (60.5%) were men, 143 (71.5%) were African Americans, and 33 (16.5%) were Latino. Common presenting symptoms were cough 130 (65.0%), shortness of breath 129 (64.5%), and fever 121 (60.5%). One or more comorbid illness occurred in 171 (85.5%) and common comorbidities were hypertension (130 (65.2%)), diabetes (100 (50.0%)) and chronic kidney disease (60 (30.0%)). Of the 200 patients, 71 (35.5%) were treated in the ICU, 47 (24.2%) received mechanical ventilation, 45 (22.5%) died, and 155 (77.5%) patients discharged home alive. The non-survivors were significantly older and had elevated markers of inflammation, coagulation, and acute organ damage on presentation. Age ≥ 65 years (odds ratio (OR), 3.78; 95% CI, 1.74–8.22; \( P = .001 \)), lactate dehydrogenase level > 400 IU/L (OR, 9.1; 95% CI, 2.97–28.1; \( P < 0.001 \)), C-reactive protein > 20 mg/dl (OR, 5.56; 95%CI, 1.84–16.8; \( p < 0.001 \)), ferritin > 2000 ng/ml (OR, 5.42; 95%CI, 1.63–17.9; \( p = 0.006 \)), creatinine kinase > 1000 iu/l (OR, 5.42; 95%CI, 1.63–17.9; \( p = 0.006 \)), creatinine > 2 mg/dl (OR, 4.5; 95% CI, 1.29–15.8; \( P = 0.018 \)) at admission were associated independently with increases risk of in-hospital mortality.

Conclusion Patients of advanced age that present with elevated biomarkers of inflammation, coagulation, and end-organ damage were at higher risk of mortality.

Keywords COVID-19 · Inflammation · Thrombosis · Mortality · Minority

Introduction
Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality. More than 1,270,000 worldwide and approximately 239,600 patients in the United States (US) have died since December 2019 [1]. Preliminary data indicate that minority populations such as African Americans (AA) and Latinos are contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at higher rates and are more likely to die, bearing a disproportionate burden in the US [2, 3]. For example, in the District of Colombia (DC), as of November 9, 2020, out of total of 18,173 COVID-19 cases and 657 deaths, 8850 cases and 490 deaths occurred in Black/AA race accounting for 48.7% of the cases and 74.6% of deaths despite AA composing only 46% of the district’s population. The disproportionate impact of the coronavirus among AA and other minority populations meanwhile, is not limited to the District. Counties that are majority Black were reported to have three times the rate of infections and almost six times the rate of deaths as counties...
where white residents are in the majority [4]. A similar observation was noted in the District of Columbia ward level comparison data, with Ward 8 Black residents (92% Black) having the highest deaths (126 deaths) compared to Ward 3 majority White (81% White) residents having 34 deaths as of September 23, 2020 [5].

Multiple factors including patients’ age and comorbidities have been recognized in increasing the risk of hospital admission and predicting worse outcomes [6–10]. However, data fully adjusted for comorbidities and laboratory markers to the reported differences in fatality rates among AA and other minority patients are limited. The early outcome predictors in those at high risk to be infected and to die if infected is not well-known. Our objective was to identify the early mortality predictors. In this study, we collected the demographics, baseline comorbidities, presenting clinical and laboratory data, and we report the clinical characteristics and the independent predictors of mortality of patients with COVID-19 hospitalized at an academic inner city hospital in Washington DC.

**Methods**

**Study Design and Participants**

The study was approved by the Howard University institutional review board as a minimal risk research, and the requirement for informed consent was waived. Consecutive adult patients admitted with COVID-19 between March 1 and May 30, 2020 were included. COVID-19 was confirmed with reverse-transcriptase–polymerase-chain-reaction assay (RT-PCR) of nasopharyngeal specimens.

**Data Collection and Definitions**

Demographics, comorbidities, clinical presentation, initial laboratory data, and inpatient treatments including invasive mechanical ventilation and new renal replacement therapy, intensive care unit (ICU) admission, discharge status, and survival status were extracted from electronic records manually. Obesity was defined as body mass index (BMI) $\geq 30$ kg/m$^2$. Initial laboratory data was the first test results available, typically within 24 h of admission which included complete blood count, basic metabolic panel, ferritin, procalcitonin (PCT), C-reactive protein (CRP), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), troponin, D-dimer, and interleukin-6 levels. Acute kidney injury (AKI) was defined as increase in serum creatinine of $> 0.3$ mg/dl from baseline present on admission. [11]

**Outcomes**

Primary outcome was in-hospital mortality. Secondary outcomes were need for intensive care unit (ICU) admission, mechanical ventilation, new renal replacement therapy (HD), and vasopressors.

**Statistical Analysis**

Explanatory analysis using Pearson’s Chi Square test, Student’s t test, and Fischer’s exact test were performed as appropriate. Categorical variables were shown by frequencies and percentages. Continuous variables were shown as mean ± standard deviation (SD) or transformed into ordered categorical variables. Continuous variables were transformed into ordered categorical variable to enable the assessment of linearity of association in the regression analysis. Ordered categorization of these continuous variables was based on clinical significance and distribution of respective range of values. Initial laboratory values were categorized into 3 groups viz. serum creatinine (Scr) $< 1, 1–2, > 2$ mg/dl; blood urea nitrogen (BUN) $< 25, 25–35, > 35$ mg/dl; CPK $< 250, 250–1000, > 1000$ iu/l; troponin $< 0.05, 0.05–0.10, > 0.10$ ng/ml; procalcitonin $< 0.5, 0.5–2.5, > 2.5$ ng/ml; LDH $< 300, 300–400, > 400$ iu/l; CRP $< 10, 10–20, > 20$ mg/dl; D-dimer $< 1, 1–3, > 3$ μg/ml and ferritin $< 500, 500–2000, > 2000$ ng/ml. Lactic acid level was categorized into 2 groups of $< 2.2$ and $> 2.2$ mm/l. Multivariable logistic regression models were performed to identify independent factors associated with inpatient mortality. Variables with significant association in the univariable analysis were included in the multivariable analysis. A base multivariable regression model was performed with variables identified to be statistically significant among patients’ demographics and baseline comorbid conditions in the univariable analysis. To avoid overfitting, we rerun the base model with each of the laboratory/inflammatory markers each at a time to determine the independence of each laboratory/inflammatory maker as a predictor of mortality. We also created receiver operating characteristics (ROC) curves to compare mortality prediction among the various initial inflammatory markers, which were summarized by area under the curve (AUC) estimates among the various models. The analysis was performed using STATA statistical software version 14.1 (Statacorp, College Station, Texas). Statistical significance was accepted at $P$ value $< 0.05$.

**Results**

**Demographics and Patient Characteristics**

A total of 200 patients were admitted to hospital during the study period. The mean (SD) age was 58.9 (15.1) years, 121
(60.5%) were men, 143 (71.5%) were Black/AA, and 33 (16.5%) were Latino patients. One or more underlying comorbid illness occurred in 171 (85.5%) of the patients. Most common comorbidities were hypertension (HTN) 130 (65.0%), diabetes mellitus (DM) 100 (50.0%), chronic kidney disease (CKD) 60 (30.0%), and cardiovascular diseases 56 (28.5%) as shown in Table 1.

Common presenting symptoms were cough 130 (65.0%), fever 121 (60.5%), and shortness of breath (SOB) 129 (64.5%) shown in Table 2. Admission laboratory data showed lymphopenia (lymphocyte count, 1.1 × 10^9 per L [mean 0.65 × 10^9 per L]), elevated markers of inflammation, coagulation, and acute organ damage as shown in Table 2.

### Outcomes and Predictors for Mortality

In-hospital mortality occurred in 45 (22.5%) patients. Compared with survivor group, non-survivors were older (67.1 ± 13.7 vs. 58 ± 14.9 years; \( p < 0.001 \)). Comorbidities, such as HTN (77.8% vs. 61.3%; \( p = 0.04 \)), CKD (42.2% vs 26.5%; \( p = 0.04 \)), CAD (26.7% vs. 13.6%; \( p = 04 \)) were higher in those deceased when compared to those discharged alive respectively (Table 1). The non-survivor group had higher markers of inflammation, including a higher serum CRP (17.1 ± 8.8 vs. 11.6 ± 8.2 mg/dl; \( p < 0.001 \)), procalcitonin, LDH, CRP, and ferritin level were all independent predictors of mortality. After adjustment for important variables (variables in the base model), patients with initial LDH level > 400 IU/l vs. with < 300 IU/l had a 9-fold greater risk of inpatient mortality (OR, 9.1; 95% CI – 2.97 to 28.1; \( p < 0.001 \)), and initial CRP > 20 mg/dl had 6-fold greater risk for mortality than CRP < 10 mg/dl (OR, – 5.56; 95% CI, – 1.84 to 16.8; \( p < 0.001 \)). The same linear trend was noted for initial ferritin, CPK, BUN, creatinine, and procalcitonin levels, with initial ferritin > 2000 ng/ml conferring a 5-fold greater risk than level < 500 ng/ml (OR 5.4; 95% CI, – 1.63 to 17.9; \( p = 0.006 \)) and CPK > 10000iu/l conferring 3.6-fold greater risk than those within the normal reference range (OR, 3.57; 95% CI, – 1.23 to 10.3; \( p = 0.019 \)) Table 3. Kidney function at the time of presentation was also an important independent predictor of mortality, patients with initial creatinine level > 2 mg/dl in non-dialysis dependent patients was associated with 4.5-fold greater risk of mortality compared with < 1 mg/dl creatinine level (OR, 4.5; 95% CI 1.29 = 15.8; \( p = 0.018 \)). The patient group with initial procalcitonin level of 2.5 ng/ml had 4-fold mortality risk compared with procalcitonin < 0.5 ng/ml (OR, 4.21; 95% CI, 1.47–12.0; \( p = 0.007 \)). Initial D-dimer level was not found to be an independent predictor of mortality; however, rapid increase in D-dimer level and peak D-dimer during hospitalization was the strongest independent predictor of mortality. A peak D-dimer level > 3.0 μg/ml conferred 24-fold mortality risk compared with peak D-dimer level < 3.0 μg/ml.

Both initial LDH and CRP were identified as independent predictor of unfavorable outcomes for both ICU admission and inpatient mortality. Area under the curve (AUC) estimates among the different models (Fig. 2), identified initial LDH (AUC 0.84), followed by initial CRP (AUC 0.79) as the two most important laboratory/inflammatory markers to predict unfavorable outcomes in our study. LDH appeared to be a better prognosticator of inpatient mortality among the laboratory markers with mortality rates ranging 9.8% in patients with initial LDH < 300 IU/l to 38.4% in patients with initial LDH > 400 IU/l (Fig. 1). Two-thirds of all inpatient mortality in our study population occurred in patients with initial LDH of 400 IU/l and above. A ROC curve for in-hospital mortality had an estimated AUC of 0.74 for LDH alone followed by 0.69 for CRP alone.

### Discussion

This retrospective cohort study identified older age, elevated biomarkers of inflammation, rising coagulation marker, and markers of acute organ damage at presentation were associated with higher odds of in-hospital mortality.
Specifically, age $\geq 65$ years, elevated admission serum levels of LDH, CRP, ferritin, PCT, CPK, troponin, BUN and Scr, and rising D-dimer level all had an independent increased risk of in-hospital mortality. Elevated admission serum LDL and CRP levels were also independent predictors for ICU admission. These biomarkers can help in the early identification of patients that progress rapidly to severe acute respiratory distress syndrome (ARDS), multi-organ failure, and death.

Among the biomarkers, elevated serum LDH level at admission had a better predictive ability. Serum LDH > 400 IU/l was associated with a 9-fold increase in odds of hospital mortality. A finding similar to a study that performed a pooled analysis from studies [12, 13] with a total of 514 patients [14].

### Table 1 Baseline characteristics of hospitalized patients with COVID-19 by survival status

| Characteristics                      | All (N=200) | Non-survivors (n=45) | Survivors (n=155) | p value |
|--------------------------------------|-------------|----------------------|-------------------|---------|
| Age mean, (SD), yr.                 | 58.9 (15.1) | 67.1 (13.7)          | 58 (14.9)         | <0.001  |
| Age group, no. (%)                  |             |                      |                   |         |
| <65 yr                               | 122 (61.0)  | 15 (33.3)            | 107 (69.0)        | <0.001  |
| $\geq$65 yr                          | 78 (39.0)   | 30 (66.7)            | 48 (31.0)         |         |
| Gender, no. (%)                      |             |                      |                   |         |
| Male                                 | 121 (60.5)  | 29 (64.4)            | 92 (59.4)         | 0.540   |
| Female                               | 79 (39.5)   | 16 (35.6)            | 63 (40.6)         |         |
| Race, no. (%)                        |             |                      |                   |         |
| African American                     | 143 (71.5)  | 35 (77.8)            | 108 (69.7)        | 0.500   |
| Hispanic/Latino                      | 33 (16.5)   | 5 (11.1)             | 28 (18.1)         |         |
| White                                | 15 (7.5)    | 3 (6.7)              | 12 (7.7)          |         |
| Others                               | 9 (4.5)     | 2 (4.4)              | 7 (4.5)           |         |
| Insurance, no. (%)                   |             |                      |                   |         |
| Medicare                             | 21 (10.5)   | 5 (11.1)             | 16 (10.3)         |         |
| Medicaid alone                       | 24 (12.0)   | 4 (8.9)              | 20 (12.9)         |         |
| Medicaid and other a                 | 79 (39.5)   | 27 (60.0)            | 52 (33.6)         | 0.020   |
| Private                              | 59 (29.5)   | 8 (17.8)             | 51 (32.9)         |         |
| Uninsured                            | 17 (8.5)    | 1 (2.2)              | 16 (10.3)         |         |
| Referral, no. (%)                    |             |                      |                   |         |
| Community                            | 137 (68.5)  | 24 (53.3)            | 113 (72.9)        | 0.009   |
| Nursing home residents               | 46 (23.0)   | 19 (42.2)            | 27 (17.4)         | 0.001   |
| Homelessness                         | 17 (8.5)    | 2 (4.4)              | 15 (9.7)          | 0.270   |
| Body mass index, no. (%)             |             |                      |                   |         |
| 18.5–24.9, kg/m²                      | 45 (22.5%)  | 11 (24.4%)           | 34 (21.9%)        | 0.490   |
| 25–29.9, kg/m²                        | 64 (32.0%)  | 16 (35.6%)           | 48 (31%)          |         |
| $\geq$30, kg/m²                       | 74 (37.0%)  | 14 (31.1%)           | 60 (38.7%)        |         |
| Body mass index, kg/m², mean, (SD)   | 30 (9)      | 28.3 (8.3)           | 30.6 (9.2)        | 0.14    |
| Comorbidities, no. (%)               |             |                      |                   |         |
| Diabetes mellitus                    | 100 (50.0)  | 26 (57.8)            | 74 (47.7)         | 0.240   |
| HbA1C, mean (SD)                     | 7.7 (2.6)   | 7.3 (2.5)            | 7.8 (2.6)         | 0.32    |
| Hypertension                         | 130 (65.0)  | 35 (77.8)            | 95 (61.3)         | 0.04    |
| Coronary artery disease              | 33 (16.5)   | 12 (26.7)            | 21 (13.6)         | 0.04    |
| Congestive heart failure             | 26 (13.0)   | 4 (8.9)              | 22 (14.2)         | 0.35    |
| Cardiovascular diseases b            | 56 (28.0)   | 15 (33.3)            | 41 (26.5)         | 0.36    |
| Dyslipidemia                         | 69 (34.5)   | 24 (53.3)            | 45 (29.0)         | 0.003   |
| Chronic kidney disease               | 60 (30.0)   | 19 (42.2)            | 41 (26.5)         | 0.04    |
| ESRD on dialysis                     | 27 (13.5)   | 4 (8.9)              | 23 (14.8)         | 0.30    |
| History of stroke                    | 22 (11.0)   | 9 (20.0)             | 13 (8.4)          | 0.03    |
| COPD                                 | 19 (9.5)    | 7 (15.6)             | 12 (7.7)          | 0.11    |
| Asthma                               | 20 (10.0)   | 3 (6.7)              | 17 (11)           | 0.39    |
| Chronic lung disease c               | 41 (20.5%)  | 9 (20%)              | 32 (20.7%)        | 0.93    |
| Comorbidities, no. (%)               |             |                      |                   |         |
| Hepatitis B                          | 3 (1.5)     | 0 (0.0)              | 3 (1.9)           | 0.34    |
| Hepatitis C                          | 5 (2.5)     | 2 (4.4)              | 3 (1.9)           | 0.34    |
| HIV                                  | 14 (7.0)    | 4 (8.9)              | 10 (6.5)          | 0.57    |
| Malignancy d                         | 13 (6.5)    | 3 (6.7%)             | 10 (6.5)          | 0.95    |
| Dementia                             | 24 (12.0)   | 10 (22.2)            | 14 (9.0)          | 0.01    |

*COPD*, chronic obstructive lung disease; *ERSD*, end-stage renal disease; *HIV*, human immunodeficiency virus; *HbA1C*, hemoglobin A1C

a Insurance status of Medicaid and others is combination of Medicaid with any other insurance

b Cardiovascular Diseases (cardiovascular diseases variable is combined CAD, CHF, atrial fibrillation, and PAD)

c Chronic lung diseases (combination of COPD, asthma, and obstructive sleep apnea)

d Malignancy both active and in remission
and others that reported, LDH to be associated with worse outcomes in patients severe COVID-19 [15] and other viral pneumonia [16]. Studies from the USA that included AA patients [7, 17, 18] reported, LDH to be associated with disease severity but none of these studies showed its independent association with mortality. Except, a study with no race ethnic information from the DC [19], where AA accounted for 74% of COVID-19-related mortality, showed an 8-fold increased odds of death occurred when the LDH level was greater than 1200 units/l, a finding similar to our study. LDH is present in lung tissue (isozyme 3) and patients with severe COVID-19 infections can have elevated LDH in the circulation. Additionally, LDH levels can be elevated in patients from cytokine mediated multiple organ injury [14, 20].

Table 2 Presenting symptoms and admission laboratory results of hospitalized patients with COVID-19 by survival status

| Characteristics                                      | All, N=200 | Non-survivors (n=45) | Survivors (n=155) | p value |
|------------------------------------------------------|------------|----------------------|-------------------|---------|
| Presenting symptoms, no. (%)                         |            |                      |                   |         |
| Fever                                                | 121 (60.5) | 20 (44.4)            | 101 (65.2)        | 0.01    |
| Shortness of breath                                  | 129 (64.5) | 28 (62.2)            | 101 (65.2)        | 0.71    |
| Cough                                                | 130 (65.0) | 24 (53.3)            | 106 (68.4)        | 0.06    |
| Chest pain                                           | 19 (11.1)  | 0 (0.0)              | 19 (13.9)         | 0.02    |
| Myalgia                                              | 90 (45.0)  | 14 (31.1)            | 76 (49.0)         | 0.03    |
| Altered mental status                                | 32 (19.5)  | 11 (24.4)            | 21 (13.5)         | 0.07    |
| Headache                                             | 20 (11.6)  | 0 (0.0)              | 20 (12.9)         | 0.01    |
| Diaphores                                            | 23 (11.5)  | 6 (13.3)             | 17 (11.0)         | 0.66    |
| Vomitting                                             | 26 (13.0)  | 6 (13.3)             | 20 (12.9)         | 0.94    |
| Loss of appetite                                      | 48 (24.1)  | 13 (28.9)            | 35 (22.6)         | 0.38    |
| Abdominal pain                                        | 21 (12.2)  | 4 (8.9)              | 17 (11.0)         | 0.69    |
| Initial vital signs, no. (%)                         |            |                      |                   |         |
| Hypotension (SBP <90 mmHg)                            | 9 (4.5)    | 2 (4.4)              | 7 (4.5)           | 0.98    |
| Tachycardia (HR >100 beats per minute)               | 68 (34.0)  | 18 (40.0)            | 50 (32.2)         | 0.33    |
| Tachypnea (RR >20 per minute)                        | 38 (17)    | 13 (28.9)            | 25 (16.1)         | 0.06    |
| Fever (T >38.0 °C)                                    | 55 (27.5)  | 7 (15.6)             | 48 (31)           | 0.05    |
| Need for supplemental oxygen                          | 67 (36.6)  | 20 (44.4)            | 47 (30.3)         | 0.08    |
| AKI on presentation                                   | 65 (32.5)  | 27 (60.0)            | 38 (24.7)         | <0.001  |
| Admission laboratory results, mean (SD)              |            |                      |                   |         |
| White blood cell, ×10^9 per L                         | 7.8 (4.1)  | 8.8 (4.2)            | 7.5 (4.0)         | 0.06    |
| Hemoglobin, g/dL                                      | 12.4 (2.4) | 12.7 (2.0)           | 12.3 (2.6)        | 0.33    |
| Platelets, µL/L × 10^9 per L                          | 217 (90)   | 200 (74)             | 222 (94)          | 0.14    |
| Absolute neutrophil count, ×10^6 per L               | 5.9 (3.9)  | 6.8 (4.20)           | 5.6 (3.8)         | 0.06    |
| Absolute lymphocyte count, ×10^9 per L               | 1.15 (0.65)| 1.1 (0.70)           | 1.16 (0.64)       | 0.55    |
| Complete metabolic panel, mean (SD)                  |            |                      |                   |         |
| Admission BUN, mg/dLb                                 | 28.09 (29.4)| 41.9 (29.3)          | 23.7 (28.1)       | <0.001  |
| Admission creatinine, mg/dLb                         | 1.60 (1.91)| 2.16 (1.60)          | 1.42 (1.97)       | 0.03    |
| Albumin, g/dl                                        | 3.5 (5.4)  | 3.3 (5.2)            | 3.5 (5.3)         | 0.007   |
| Alkaline phosphatase, IU/L                           | 86.2 (94.0)| 122 (176)            | 75 (42)           | 0.003   |
| AST, IU/L                                            | 74.0 (235.0)| 108 (258.0)          | 64 (228.0)        | 0.27    |
| ALT, IU/L                                            | 51.8 (187.0)| 51 (79.0)            | 51 (209.0)        | 0.99    |
| Total bilirubin, mg/dl                               | 0.64 (0.67)| 0.70 (0.72)          | 0.63 (0.66)       | 0.50    |
| Marker of inflammation/tissue damage, mean (SD)      |            |                      |                   |         |
| Admission CPK, IU/L                                  | 1111.6 (6699.3)| 3107 (13150)        | 439 (857)         | 0.024   |
| Admission troponin, ng/ml                            | 0.14 (0.77)| 0.11 (0.22)          | 0.08 (0.26)       | 0.427   |
| Admission procalcitonin, ng/ml                       | 2.74 (11.3)| 2.69 (4.8)           | 1.90 (9.14)       | <0.001  |
| Admission lactate acid, mm/l                         | 1.50 (0.82)| 1.79 (1.02)          | 1.41 (0.73)       | <0.001  |
| Admission LDH, IU/L                                  | 397 (234.3)| 561 (330.0)          | 352 (177.0)       | <0.001  |
| Admission CRP, mg/dl                                 | 12.8 (8.6)| 17.1 (8.8)           | 11.6 (8.2)        | <0.001  |
| Admission D-dimer, µg/ml                             | 2.68 (3.87)| 3.68 (5.09)          | 2.40 (3.43)       | 0.063   |
| Admission ferritin, ng/ml                            | 1004 (1461)| 1592 (2259)          | 839 (1097)        | 0.003   |
| IL-6, pg/ml                                          | 189.9 (373.1)| 372.8 (575.3)        | 127 (251)         | 0.007   |
| Highest D-dimer, µg/ml                               | 4.67 (5.72)| 9.83 (7.54)          | 3.19 (4.0)        | <0.001  |
| Highest ferritin, ng/ml                              | 1317 (1994)| 2219 (3037)          | 1062 (1499)       | <0.001  |
| Highest troponin, ng/ml                              | 0.38 (1.51)| 0.82 (2.28)          | 0.24 (1.15)       | 0.030   |

AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, C-reactive protein; CPK, creatine phosphokinase; HR, heart rate; IL-6, interleukin-6; LDH, lactate dehydrogenase; RR, respiratory rate; SBP, systolic blood pressure

a Hypotension was defined as systolic blood pressure < 90 mmHg. Tachycardia was defined as heart rate > 100/min and tachypnea was defined as respiratory rate > 20/min

bc Values excluding ESRD patients
In addition, markers of acute cardiac injury using an elevated troponin and CPK and acute kidney injury (AKI) using admission sScr and BUN were independent predictors of mortality in this study. These findings are similar to previous studies that reported myocardial injury as indicated by elevated troponin with severe COVID-19 and the association with higher mortality [21–23]. Scr > 2 mg/dl had a 4-fold increased risk and BUN > 35 mg/dl close to 5-fold increase in odds of mortality in this study. Acute kidney injury was reported in critically ill COVID-19 in studies from the USA [7], China [24], and Italy [25], and was associated with a higher risk of mortality [26, 27]. SARS-CoV-2 might cause organ injury through direct and indirect pathogenic pathways such as immune activation, dehydration, hypoxemia, and acid-base imbalances [25]. In addition, most COVID-19 patients are older and have comorbidities such as HTN and DM, well-known factors for both cardiac and renal vulnerability [28].

In addition to the biomarkers of acute organ damage, a rising D-dimer was also associated with increased odds death in this study. Elevated D-dimer, an indirect marker of coagulation activation, has been reported to be associated with severity of illness and mortality among hospitalized patients with COVID-19 [29, 30]. In this study, we found those who died had 3-fold increased D-dimer levels than those who survived which is similar to an observation by Tang et al. [31] that reported, D-dimer values were nearly 3.5-fold higher in those who died than in those who survived. Similarly, a study that included 138 patients [32], D-dimer values were nearly 2.5-fold higher in COVID-19 patients with severe disease than in those without. We found the rising D-dimer had the largest increase in odds of mortality. A peak D-dimer between 3 and 6 μg/ml was associated with 11-fold increased risk and D-Dimer> 6 μg/ml having 24-fold increased risk of mortality suggesting a dynamic measurement of D-dimer might reveal more information [33, 34]. Similar observation was reported by others, that D-dimer and rising D-dimer linked to mortality [31]. The observed elevation of D-dimer might be due to direct viral-related endothelial injury [35] and other known thrombosis risk factors [36–38]. Additionally, the D-dimer elevation can be seen in some patients due to sepsis-induced coagulopathy [39]. These findings all together suggest D-dimer elevation is associated with poor outcomes and the consideration of anticoagulation in hospitalized patients with COVID-19 [40, 41].

With respect to inflammatory biomarkers, significantly increased levels of CRP, IL-6, ferritin, and PCT were observed at admission in the non-survivors. A similar observation was reported by several studies [12, 17, 42, 43]. In multivariate analysis, CRP, PCT, and high ferritin were also independent predictors of mortality. A CRP level > 20 mg/dl had 6-fold higher odds of in-hospital mortality which was also reported by others [19]. A 4-fold higher risk of mortality occurred for patients who had elevated PCT in this study, which is similar to a study [44], that reported PCT associated with a nearly 5-
# Table 3

Univariate and multivariate analysis of mortality predictors hospitalized patients with coronavirus disease 2019

| Variable                        | N (%) | Univariable | Multivariable |
|---------------------------------|-------|-------------|---------------|
|                                |       | OR     95% CI | P value       | OR     95% CI | P value |
| Age ≥65 yrs vs <65 yrs          | 78 (39)| 4.45 2.19–9.04 | <0.001       | 3.78 1.74–8.22 | 0.001   |
| Female gender                   | 79 (39.5)| 0.81 0.40–1.60 | 0.54         |           |         |
| Race—Black                      | 143 (71.5)| 1.52 0.69–3.32 | 0.29         |           |         |
| Current or ex-smoker            | 50 (25)| 1.71 0.83–3.54 | 0.14         |           |         |
| Body mass index, kg/m²          |       |           |              |
| 18.5–24.9                       | 45 (22.5)| Ref.     |              |           |         |
| 25–29.9                         | 64 (32)| 0.89 0.39–2.03 | 0.79         |           |         |
| ≥30                             | 74 (37)| 0.61 0.27–1.38 | 0.24         |           |         |
| Hypertension                    | 130 (65)| 2.21 1.02–4.79 | 0.04         | 0.89 0.34–2.32 | 0.81   |
| Diabetes mellitus               | 100 (50)| 1.49 0.77–2.93 | 0.23         | 1.11 0.43–2.85 | 0.82   |
| Coronary artery disease         | 33 (16.5)| 2.32 1.04–5.19 | 0.04         |           |         |
| Heart failure                   | 26 (13)| 0.59 0.19–1.81 | 0.36         |           |         |
| Dyslipidemia                     | 69 (34.5)| 2.79 1.41–5.51 | 0.003        | 2.12 0.94–4.77 | 0.07   |
| Lung diseases                   | 37 (18.5)| 1.13 0.49–2.61 | 0.79         |           |         |
| Chronic kidney disease          | 60 (30)| 2.03 1.02–4.05 | 0.04         | 1.25 0.56–3.01 | 0.54   |
| Chronic hemodialysis            | 27 (13.5)| 0.56 0.18–1.71 | 0.31         |           |         |
| History of stroke               | 22 (11.0)| 2.73 1.08–6.88 | 0.03         | 1.34 0.45–4.02 | 0.59   |
| Vital signs on presentation     |       |           |              |
| Systolic BP, mmHg               | 200 (100)| 0.99 0.98–1.01 | 0.70         |           |         |
| Diastolic BP, mmHg              | 200 (100)| 0.98 0.97–1.01 | 0.37         |           |         |
| Heart rate, b/m                 | 200 (100)| 1.00 0.98–1.02 | 0.78         |           |         |
| Respiratory rate, b/m           | 200 (100)| 1.06 0.98–1.15 | 0.10         |           |         |
| Oxygen saturation (%)           | 200 (100)| 0.89 0.82–0.97 | 0.01         | 0.84 0.76–0.93 | 0.001  |
| Admission laboratory variable   |       |           |              |
| Creatinine, mg/dl **            |       |           |              |
| <1                              | 75 (43.4)| Ref.     |              | Ref.     |         |
| 1–2                             | 67 (38.7)| 3.07 1.23–7.64 | 0.016        | 2.45 0.91–6.55 | 0.074  |
| >2                              | 31 (17.9)| 7.85 2.84–21.7 | <0.001       | 4.51 1.29–15.8 | 0.018  |
| BUN, mg/dl b**                  |       |           |              |
| <25                             | 117 (67.6)| Ref.     |              | Ref.     |         |
| 25–35                           | 21 (12.1)| 4.2 1.48–11.8 | 0.007        | 3.71 1.12–12.2 | 0.031  |
| >35                             | 35 (20.3)| 7.2 3.06–16.9 | <0.0001      | 4.73 1.63–13.6 | 0.004  |
| CPK, IU/L*                      |       |           |              |
| <250                            | 95 (55.9)| Ref.     |              | Ref.     |         |
| 250–1000                        | 51 (30.0)| 4.06 1.81–9.16 | 0.001        | 3.49 1.47–8.25 | 0.004  |
| >1000                           | 24 (14.1)| 4.51 1.66–12.2 | 0.003        | 3.57 1.23–10.3 | 0.019  |
| Troponin, ng/ml*                |       |           |              |
| <0.05                           | 122 (69.7)| Ref.     |              | Ref.     |         |
| 0.05–0.10                       | 30 (17.1)| 2.95 1.22–7.14 | 0.016        | 1.92 0.69–5.32 | 0.20   |
| >0.10                           | 23 (13.2)| 5.56 2.15–14.4 | 0.001        | 2.92 0.98–8.70 | 0.06   |
| Procalcitonin, ng/ml*           |       |           |              |
| <0.5                            | 93 (58.9)| Ref.     |              | Ref.     |         |
| 0.5–2.5                         | 35 (22.2)| 1.55 0.68–3.79 | 0.329        | 1.74 0.63–4.81 | 0.28   |
| >2.5                            | 30 (18.9)| 3.89 1.62–9.34 | 0.002        | 4.21 1.47–12.0 | 0.007  |
| Lactic acid, mm/l*              |       |           |              |
| <2.2                            | 153 (82.7)| Ref.     |              | Ref.     |         |
| >2.2                            | 32 (17.3)| 2.69 1.20–6.04 | 0.016        | 1.97 0.80–4.82 | 0.13   |
fold higher risk of severe disease. Elevated PCT level indicates superimposed bacterial infection, and might help in guiding antibiotic use in critically ill patients.

About 15–20% of the COVID-19 patients require hospitalization [32]. Some of those admitted progress rapidly into a severe ARDS and multi-organ failure and death [45]. Why some individuals become critically ill, while others do not is not fully understood. In addition to viremia-induced cell damage, another mechanism leading to disease severity, complications, and death might be an aberrant inflammatory response [46]. An observation that was reported in other severe viral pneumonias, such as highly pathogenic avian influenza [47], SARS, and pandemic and seasonal influenza [48]. Our findings appear to corroborate that the inflammatory indices are independently associated with patients becoming critically ill, requiring ventilatory support and dying. It remains unclear whether these inflammatory indicators are biologic markers of disease or mediators of the hypothesized “cytokine storm,” in which excessive cytokine release results in hyperinflammation and multi-organ disease.

In the present study, the deceased group (67 ± 13.7 years) were close to one decade older than those who survived (58 ± 14.9 years) and had significantly higher comorbidities which is consistent with the observations of earlier studies [6, 7, 17, 49, 50]. Compared to those aged < 65 years, the odds of dying for patients aged ≥ 65 years was 3.78. This implies that the elderly population needs to be especially protected from contracting this virus, as they are about 4 times more likely to die independent of their comorbidities. As to why the elderly are dying? Previous studies in macaques inoculated with SARS-CoV found that older macaques had stronger host immune responses to virus infection than younger adults, with an increase in differential expression of genes associated with inflammation [51]. The age-dependent defects in T cell and B cell function and the excess production of type 2 cytokines could lead to a deficiency in control of viral replication and more prolonged proinflammatory responses, potentially leading to poor outcome in the elderly [52].

The majority of patients hospitalized with COVID-19 in this study were Black/AA followed by Latino. This findings are in line with the District COVID-19 data and

| Variable | Univariable | Multivariable |
|----------|-------------|---------------|
|          | N (%)       | OR 95% CI     | P value  | OR 95% CI     | P value  |
| LDH, IU/L* |             |               |          |               |          |
| <300     | 61 (34.3)   | Ref.          |          | Ref.          |          |
| 300–400  | 52 (29.2)   | 1.42          | 0.45–4.54 | 0.549 | 1.34          | 0.38–4.74 | 0.64          |
| >400     | 65 (36.5)   | 5.72          | 2.15–15.3 | <0.001 | 9.14          | 2.97–28.1 | <0.001 |
| CRP, mg/dl* |             |               |          |               |          |
| <10      | 75 (42.4)   | Ref.          |          | Ref.          |          |
| 10–20    | 68 (38.4)   | 2.79          | 1.11–6.79 | 0.028 | 2.57          | 0.96–6.89 | 0.060         |
| >20      | 34 (19.2)   | 5.18          | 1.89–14.2 | 0.001 | 5.56          | 1.84–16.8 | 0.002 |
| Initial D-dimer, μg/ml* |             |               |          |               |          |
| <1       | 75 (40.8)   | Ref.          |          | Ref.          |          |
| 1–3      | 68 (36.9)   | 3.06          | 1.27–7.29 | 0.012 | 1.88          | 0.72–4.90 | 0.195         |
| >3       | 41 (22.3)   | 3.03          | 1.15–7.99 | 0.025 | 2.12          | 0.73–6.13 | 0.164         |
| Ferritin, ng/ml* |             |               |          |               |          |
| <500     | 99 (52.9)   | Ref.          |          | Ref.          |          |
| 500–2000 | 64 (34.2)   | 2.02          | 0.92–4.42 | 0.076 | 2.74          | 1.11–6.70 | 0.027         |
| >2000    | 24 (12.8)   | 3.36          | 1.24–9.06 | 0.017 | 5.42          | 1.63–17.9 | 0.006         |
| Highest D-dimer, μg/ml* |             |               |          |               |          |
| <3       | 104 (57.5)  | Ref.          |          | Ref.          |          |
| 3–6      | 33 (20.4)   | 10.7          | 3.48–32.9 | <0.001 | 10.9          | 3.33–36.2 | <0.001        |
| >6       | 44 (22.1)   | 21.9          | 7.34–65.2 | <0.001 | 23.7          | 7.33–76.7 | <0.001        |

BP, blood pressure; BUN, blood urea nitrogen; CRP, c-reactive protein; CPK, creatine phosphokinase; CI, confidence interval; LDH, lactate dehydrogenase; OR, odds ratio

a,b Values excluding ESRD patients

aData was not available for all patients
that reported AA and other minority groups experiencing infection and death rates from COVID-19 that are disproportionately high for their share of the total population in the USA [2]. In Washington DC, as of September 23, 2020, AA race accounted for 51.2% of the cases and 74.4% of deaths despite AA composing only 46% of the district's population. Possible explanations are intersecting forces of racial disparities, underlying conditions, and poverty that affect how the virus spreads are some of contributing factors [2].

Our study aimed to identify an early mortality risk markers in those who are at high risk to be infected and to die if infected. In-hospital mortality occurred in 45 (22%) patients in this study. This rate is higher than that observed in Italy (7.2%) and is substantially higher than in China (2.3%) [53] but similar to that reported in the USA [7, 19, 54]. The observed differences between countries could be due to the age distribution of the population, distribution of cases in different continents, the capacity of the health care system, and how COVID-19-related death is defined. Not surprisingly, patients admitted to the ICU had higher need of invasive mechanical ventilation, acute kidney injury requiring dialysis (HD), shock, and mortality in this study. Similar findings from a study in minority patients reported 58% who required HD, 69% who needed vasoactive pressor, and 73% who needed mechanical ventilation had inpatient mortality [54]. In one of the early studies by Yang et al., among patients admitted to ICU, 28-day mortality was 61.5% [24]. Also a retrospective study from China reported 97% of patients who were intubated and 100% of those who received renal replacement therapy died during hospitalization [12]. A study from New York City reported 88% who received mechanical ventilation and 96% who received kidney replacement therapy died [7]. The association of mortality in those admitted to ICU reflected the degree of organ damage involved and hence risk of mortality.

**Fig. 2** Area under the curve (AUC) estimates among the different models. A: AUC of base model, made of variables including age, hypertension, coronary artery disease, dyslipidemia, chronic renal disease, and history of stroke; B AUC of the variables in the base model and initial LDH level; C AUC of the variables in the base model and initial CRP level; D AUC of the variables in the base model and initial ferritin level.
Strengths and Limitations

These strengths of the study are a comprehensive data from a decent number with outcomes ascertained in all patients. However, our study is retrospective from a single center, majority are African American patients; hence, might have selection bias. Further studies should build on our findings and seek to better understand the reasons for the observed high mortality. This will give prudence to the development of prevention, early diagnosis, and optimal timing of targeted approaches in therapies in minority populations who are among the highest risk of death from COVID-19 infection.

Conclusion

We identified independent of demographics and baseline comorbidities, age ≥ 65 years, biomarkers of inflammation (CRP, ferritin, IL6, PCT), marker of coagulation(D-dimer), and acute organ damage (BUN, creatinine, CK, LDH, and troponin) as independent predictors of mortality in minority patients hospitalized with COVID-19. These biomarkers can help clinicians identify patients early who are at a high risk for clinical deterioration.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s40615-020-00961-x.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infect Dis. 2020;20(5):533–4.
2. Yancy CW. COVID-19 and African Americans. JAMA. 2020;323(19):1891–2.
3. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323(24):2466–7.
4. Fouad MN, Ruffin J, Vickers SM. COVID-19 is out of proportion in African Americans. This will come as no surprise. Am J Med. 2020;S0002-9343(20)30411-3.
5. Surveillance DC. DC Corona virus data. 2020. Available from: https://coronavirus.dc.gov/data/ 23 Sept 2020.
6. Garg S, et al. Hospitalization Rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–64.
7. Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. Jama. 2020;323(20):2052–9.
8. Fang L, Karakulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. Respir Med. 2020;8(4):e21.
9. de Lucena TMC, et al. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020;14(4):597–600.
10. Paladinos L, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262.
11. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.
12. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
13. Ruan Q, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8.
14. Henry BM, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med. 2020;38(9):1722–6.
15. Henry BM, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–8.
16. Chen C-Y, et al. Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome. J Chin Med Assoc. 2005;68(1):4–10.
17. Suleyman G, et al. Clinical Characteristics and morbidity associated with Coronavirus Disease 2019 in a series of patients in Metropolitan Detroit. JAMA New Open. 2020;3(6):e2012270.
18. Mani VR, et al. At the epicenter of the American coronavirus outbreak - New York inner city hospital COVID-19 experience and current data: a retrospective analysis. J Med Internet Res. 2020.
19. Ayanian S, et al. The association between biomarkers and clinical outcomes in novel coronavirus pneumonia in a US cohort. Biomark Med. 2020;14(12):1091–7.
20. Zhang T, et al. A non-invasive laboratory panel as a diagnostic and prognostic biomarker for thrombotic microangiopathy: development and application in a Chinese cohort study. PLoS One. 2014;9(11):e11992.
21. Guo T, et al. Cardiovascular Implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):1–8.
22. Lippi G, Lovie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020.
23. Shi S, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10.
24. Yang X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81.
25. Fanelli V, et al. Acute kidney injury in SARS-CoV-2 infected patients. Crit Care. 2020;24(1):155.
26. Cheng Y, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–38.
27. Shao M, et al. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: a systematic review and meta-analysis of 40 studies and 25,278 patients. Pharmacol Res. 2020;161:105107.
28. Junkauskas SS, et al. The age-associated loss of ischemic preconditioning in the kidney is accompanied by mitochondrial dysfunction, increased protein acetylation and decreased autophagy. Sci Rep. 2017;7(1):44430.
29. Li C, et al. D-dimer triage for COVID-19. Acad Emerg Med. 2020;27(7):612–3.
30. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
31. Tang N, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. JTH. 2020;18(4):844–7.
32. Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061–9.
33. Goldin Y, et al. The diagnostic yield of D-Dimer in relation to time from symptom onset in patients evaluated for venous thromboembolism in the emergency medicine department. J Thromb Thrombolysis. 2011;31(1):1–5.
34. Mager JJ, et al. The early course of D-dimer concentration following pulmonary artery embolisation. Thromb Haemost. 2001;86(6):1578–9.
35. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38–44.
36. Harper PL, et al. D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly. Intern Med J. 2007;37(9):607–13.
37. Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost. 2011;105(Suppl 1):S43–54.
38. Kyriakoulis KG, et al. Venous thromboembolism in the era of COVID-19. Phlebology. 2020;268355520955083.
39. Iba T, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989–94.
40. Thachil J, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6.
41. Paranjpe I, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–4.
42. Chilimuri S, et al. Predictors of mortality in adults admitted with COVID-19: retrospective cohort study from New York City. West J Emerg Med. 2020;21(4):779–84.
43. Salacup G, et al. Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: a single tertiary center cohort. J Med Virol. 2020.
44. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020;505:190–1.
45. Tay MZ, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74.
46. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–7.
47. de Jong MD, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203–7.
48. Baille JK, Digard P. Influenza–time to target the host?! N Engl J Med. 2013;369(2):191–3.
49. Rodriguez-Morales AJ, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623.
50. Grasselli G, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. Jama. 2020;323(16):1574–81.
51. Smits SL, et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 2010;6(2):e1000756.
52. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis. 2005;41(Suppl 7):S504–12.
53. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. Jama. 2020.
54. Salacup G, et al. Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: a single tertiary center cohort. J Med Virol. 2020. https://doi.org/10.1002/jmv.26252.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.